Clinical Practice Guidelines for the Imaging and Treatment of Breast Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Guidelines".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 938

Special Issue Editors


E-Mail
Guest Editor
Nuclear Medicine Unit, A.O.O.R. Villa Sofia Cervello, 90146 Palermo, Italy
Interests: breast cancer; FDG PET/CT; pediatrics; nuclear medicine

E-Mail
Guest Editor
Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena Italy, 41124 Modena, Italy
Interests: PET/CT; cancers (especially breast, lung, hematological, NET); teranostic; radiomics

Special Issue Information

Dear Colleagues,

Imaging plays a critical role in the work-up of patients with breast cancer. Patients with breast cancer commonly undergo a series of imaging tests (Ultrasound, Magnetic Resonance Imaging, Computed Tomography, lymphoscintigraphy for the identification of the sentinel lymph node, bone scan, and Positron Emission Tomography) based on the different types of cancer and class of risk. The characteristics of cancer and clinical variables also determine which type of treatment is most appropriate for that specific group of patients. Evidence-based medicine, expert consensus, and multidisciplinary discussions comprising different medical societies produced guidelines for the imaging, treatment, and follow-up of patients with breast cancer. Nevertheless, these guidelines are subject to edits based on new findings of the current literature arising from daily clinical practice.

The present Special Issue solicits research on the latest advances in clinical and experimental imaging and treatment, including clinical and radiation oncology. In this context, reviews (especially systematic reviews, meta-analysis) and original articles are welcome.

Dr. Natale Quartuccio
Prof. Dr. Luca Filippi
Dr. Stefano Panareo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • mammography
  • guidelines
  • chemotherapy
  • radiotherapy
  • oncology
  • nuclear medicine
  • PET/CT
  • MRI

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 339 KiB  
Review
Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response
by Luigi Castorina, Alessio Danilo Comis, Angela Prestifilippo, Natale Quartuccio, Stefano Panareo, Luca Filippi, Serena Castorina and Dario Giuffrida
J. Clin. Med. 2024, 13(1), 154; https://doi.org/10.3390/jcm13010154 - 27 Dec 2023
Viewed by 710
Abstract
The advent of hybrid Positron Emission Tomography/Computed Tomography (PET/CT) and PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical relevance of nuclear medicine in oncology. The use of [18F]-Fluorodeoxyglucose ([18F]FDG) has also made it possible to study tumors (including breast cancer) from [...] Read more.
The advent of hybrid Positron Emission Tomography/Computed Tomography (PET/CT) and PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical relevance of nuclear medicine in oncology. The use of [18F]-Fluorodeoxyglucose ([18F]FDG) has also made it possible to study tumors (including breast cancer) from not only a dimensional perspective but also from a metabolic point of view. In particular, the use of [18F]FDG PET allowed early confirmation of the efficacy or failure of therapy. The purpose of this review was to assess the literature concerning the response to various therapies for different subtypes of breast cancer through PET. We start by summarizing studies that investigate the validation of PET/CT for the assessment of the response to therapy in breast cancer; then, we present studies that compare PET imaging (including PET devices dedicated to the breast) with CT and MRI, focusing on the identification of the most useful parameters obtainable from PET/CT. We also focus on novel non-FDG radiotracers, as they allow for the acquisition of information on specific aspects of the new therapies. Full article
Back to TopTop